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ABSTRACT: - 
Nelfinavir is a poor water-soluble antiretroviral drug with 
relatively low bioavailability. The effect of β-cyclodextrin  
on the aqueous solubility and dissolution rate of nelfinavir 
was investigated. Phase solubility studies indicated that the 
solubility of nelfinavir was significantly enhanced by 
complexing it with β- cyclodextrin. It was classified as Bs 
type indicating the 1:2 stoichiometric inclusion complexes. 
The various solid complexes prepared by physical mixture, 
Kneading, coprecipitation & common solvent methods 
were characterized by DSC, X-RD & FT-IR. Dissolution 
study showed that the solubility and dissolution rate of 
nelfinavir was significantly improved by complexation with 
β-cyclodextrin. 
KEYWORDS: - β-cyclodextrin, physical mixture, 
Kneading Method, coprecipitation & common solvent 
method. 
 
1. INTRODUCTION: - 
Nelfinavir mesylate is an antiretroviral drug which belongs 
to class of protease inhibitors (PIs), chemically it is [3S-
[2(2S*,3S*),3a,4ab,8ab]]-N-(1,1-dimethylethyl)decahydro-
2-[2-hydroxy-3-[(3-hydroxy-2methylbenzoyl)amino]-4-
(phenylthio)butyl]-3-isoquinoline carboxamide mono-
methanesulfonate(salt). NFV is white to off-white 
amorphous powder, practically insoluble in water1and 
freely soluble in methanol, ethanol, isopropyl alcohol and 
propylene glycol2. Because of its poor water solubility,its 
absorption is dissolution rate limited.3,4,5 NFV is one 
example of drugs that lose their efficacy upon reaching the 
lower portion of the GI tract. It is soluble in acidic 
environment. It was reported that portions of the drug 
which is undissolved cannot be absorbed. Portions of drug 
that are dissolved but not yet absorbed when they pass from 
the stomach into small intestine may undergo precipitation 
and lose their therapeutic efficacy. It was confirmed by the 
fact that the presence of food in GI tract significantly 
increases the extent of absorption of oral NFV5. 
 Although scientists had been achieved remarkable success 
in AIDS therapy, enormous challenges still remains for the 
researchers to ultimately halt the progression and find a 
cure for AIDS. Currently available anti-HIV agents have 
relatively short half-life, low bioavailability, poor CNS 
penetration, retention and undesirable side effects. By 
considering above, since HIV is global problem, we have 
identified NFV-a protease inhibitor and efforts have been 
directed to develop more suitable formulation with 
improved bioavailability so as to reduce dose, side effects 
and subsequently the cost of HIV/AIDS therapy.  
The solubility of a poorly soluble drug can be altered in 
many ways, such as modification of drug crystal forms, 
addition of cosolvants, addition of surfactants, 
complexation with cyclodextrins etc. Out of these methods, 
the cyclodextrin approach is of particular interest. Hence in 
this investigation inclusion complexation of nelfinavir was 
tried with β-cyclodextrin (β-CD) with an aim to improve its 
pharmaceutical properties (i.e. aqueous solubility and 
dissolution properties). The complex of NFV with β-CD  
was prepared by using various methods at 1:2  
stoichiomeric ratio6.The characterization of drug, β-CD & 
various complexes were done by using powder x-ray 
diffractometry (PX-RD). FTIR analysis of drug, β-CD & 
various complexes was carried out to study the interaction 
between drug &polymer. In vitro aqueous solubility and 
dissolution rate profile of the complexes were 
studied.Cyclodextrins are cyclic (α-1, 4) - linked 
oligosaccharides of α-D glucopyranose, containing a 
relatively hydrophobic central cavity and hydrophilic outer 
surface. Due to lack of free rotation about the bonds 
connecting the glucopyranose units, the cyclodextrins are 
not perfectly cylindrical molecules but are toroidal or cone 
shaped. Depending upon those models, the primary 
hydroxyl groups are located on the narrow side of the cone 
shape, while secondary hydroxyl groups are located on the 
wider edge. From last two decades, CDs and their 
derivatives have been of considerable interest in the 
pharmaceutical field because of their ability to form 
complexes with a variety of drug molecules7. Cyclodextrins 
are capable to increase the solubility of water insoluble 
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drugs, by means of inclusion complex formation8,9,10,11. The 
hydrophobic cavity of cyclodextrin is capable of trapping a 
varity of molecule within to produce inclusion complexes. 
Many advantage of drugs complexed with cyclodextrins 
have been reported in scientific literature which includes-
improvement of solubility, enhancement of dissolution rate 
and bioavailability, active stabilization, odour or taste 
masking, reduced volatility, transformation of liquid or gas 
into solid form, compatibility improvement, irritation 
reduction and reduced side effects12,13. They have found 
wide application in the food and flavor industry14, cosmetic 
industery15, packing industry16, textile17, fermentation18, 
and catalysis fields19. 
2.  MATERIALS AND METHODS: - 
2.1 Materials: - Nelfinavir mesylate was obtained as a gift 
sample from Emcure pharmaceuticals Ltd., Pune, India and 
β-CD was from SA pharmachem Pvt. Ltd. Mumbai. All 
other reagents and solvents were of analytical grade. 
2.2 Phase Solubility Studies: - 
The phase solubility technique illustrates the evaluation of 
the affinity between β-CD  and nelfinavir in water. The 
solubility measurements of nelfinavir mesylate with β-CD 
were performed according to Higuchi and Connors21.An 
excess amount of drug (50mg) were added to 25 ml 
portions of distilled water, each containing variable amount 
of β-CD such as 2,4,6,8,10 and 12×10-3moles/liter. All the 
above solutions were shaken for 72hrs (100rpm) at 
25±0.50C. After shaking, solutions were filtered and their 
absorbance was noted at 254 nm using UV 
spectrophotometer (UV-1700, Shimadzu, Japan). For each 
concentration  
 
two sets are prepared and average of two readings was 
considered. The solubility of the NFV in every β-CD 
solution was calculated and phase solubility diagram was 
drawn between solubility of NFV and different 
concentrations of β-CD. The apparent stability constant 
(Kc) according to the hypothesis of 1:1 stoichiometric ratio 
of NFV: β CD complex was calculated from the phase 
solubility diagrams using following equation20. 
             Slope 
 K(1:1) =   
       S0 (1 – slope) 
The slope is obtained from the initial straight-line portion 
of the plot of NFV concentrations against β-CD 
concentration, and So is the equilibrium solubility of 
nelfinavir in water 
2.3 Preparation of Solid inclusion Complexes:- 
Solid inclusion complexes of nelfinavir with β-CD were 
prepared at 1:2 molar ratios.  
2.3.1 Physical Mixture: - 
NFV with β-CD in 1:2M ratio was mixed in a mortar for 
about one hour with constant trituration, passed through 
sieve no.100 and stored in desiccators over fused calcium 
chloride. 
2.3.2 Kneading Method: - 
NFV with β-CD in molar ratio of 1:2M was taken. First 
cyclodextrin is added to the mortar, small quantity of 50% 
ethanol (water: ethanol; 1:1v/v) is added while triturating to 
get slurry like consistency. Then slowly drug is 
incorporated into the slurry and trituration is further 
continued for one hour. Slurry is then air dried at 250C for 
24 hrs, pulverized and passed through sieve no.100 and 
stored in desiccators over fused calcium chloride. 
2.3.3 Co-precipitation Method: - 
NFV was dissolved in ethanol at room temperature and β-
CD was dissolved in distilled water. Different molar ratios 
(i.e.1: 2M) of NFV and β-CD was taken. The mixture was 
stirred at room temperature for one hour and then slowly 
evaporated on a boiling water bath. The inclusion complex 
precipitated as a crystalline powder was pulverized and 
passed through sieve no.100 and stored in desiccators till 
free from any traces of the organic solvent. 
2.4 Physicochemical characterization of Nelfinavir-CD 
solid binary systems 
 2.4.1 Powder X-ray Diffractometry: - 
The X-RD patterns of drug, β-CD & complexes were 
recorded by using an automated Philips PW 1729 X ray 
generator with filter Ni, Cu radiation over intervals 10-
800/2θ.The operation data were follows: -filter- Ni, x ray 
target-Cu, wavelength-1.542A and scanning speed 10/min. 
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2.4.3 Fourier Transform Infrared Spectroscopy: - 
Infrared spectroscopy is one of the most powerful 
analytical techniques that offer the possibility of chemical 
identification. The IR spectra of NFV and their complexes 
were obtained by KBr pellet method by JASCO-FTIR-5300 
spectrophotometer. The various IR spectra of inclusion 
complexes prepared by Physical mixture, Kneading 
method, Common solvent method and coprecipation 
method were obtained and studied for interaction patterns. 
2.5 In-vitro Dissolution Studies: - 
The In-vitro dissolution of the complex was compared with 
those of pure drug and PM. The dissolution rate studies 
were carried out in 900ml of (I) distilled water and (II) 
phosphate buffer (pH=4) using USPXXIII dissolution 
apparatus (Electrolab) with a pedal stirrer, according to 
United States pharmacopoeia (USP). The complex 
equivalent to 250mg of NFV was used in each test. The 
dissolution medium was 900 ml of distilled water & 
phosphate buffer (pH=4). The stirrer was adjusted at 50 
rpm, and the temperature was maintained at 370C±0.50C 
throughout the experiment. The samples (5ml) were 
withdrawn at various time intervals by means of a syringe 
fitted with pre-filter at known intervals of time and 
analyzed for drug release by measuring the absorbance at 
254nm after suitable dissolution with distilled water or 
phosphate buffer. 
3. RESULTS AND DISCUSSION: -   
3.1 Phase Solubility Study: - 
The phase solubility diagram for NFV: β-CD system in 
water can be characterized as Bs type phase solubility 
curve, which suggests that the molar ratio of the complexes 
is 1:2M.  Phase solubility diagram of NFV: β-CD (Bs 
type), illustrates the solubility enhancing capability of CDs. 
It shows a typical curve whose initial rising portion is 
followed by a plateau region. Further increase in β-CD 
concentration resulted in decrease in solubility but again 
increase in β-CD concentration gives an increase in the 
solubility of nelfinavir. The apparent stability constant, Kc, 
obtained from the slope CDs. Linear increase of drug 
solubility as function of CD concentration suggest AL type 
of the linear phase solubility diagram was found to be 
149.45M-1  for β-CD.   
3.2 Preparation of Nelfinavir-CD solid binary systems: - 
Solid binary systems of nelfinavir with β-CD were 
prepared using physical mixture, kneading, coprecipation. 
Based on the results obtained through the phase solubility 
studies, which proved the possibility of formation of higher 
order complexes between NFV and different cyclodextrins, 
1:2 molar ratio was chosen for the preparation of solid 
binary systems. Physical mixtures were also investigated in 
the same molar ratios for comparison. 
3.3 Powder X-Ray Diffraction: -   
The X-RD patterns of NFV: β-CD systems are represented 
in fig. (1).The diffractograms of NFV and β-CD exhibited a 
series of intense peaks which is an indicative of their 
crystalline nature. X-RD pattern of PM (NBP1) is simply 
the superimposition of each component indicating no 
formation of new structure. Complex prepared by co-
precipitation (NBC1) methods showed a diffraction pattern 
quite similar to that of PM, while those obtained from 
kneading method (NBK1) shows less peaks with low 
intensity. This indicates that the inclusion complex 
prepared by kneading method is less crystalline than the 
complexes prepared by physical mixture, common solvent 
and coprecipitation method. 
Fig.1: -X-RD Spectrum of pure drug, polymer & formulations    
(NHC1,NHP1,NHK1,NHCS1) 
    NFV 
 
NBC1 
 
NBP1 
 
NBK1 
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3.4 Fourier Transform Infrared Spectroscopy: - 
Table.No.1 Dissolution Studies of Nelfinavir Complexes 
The FT-IR spectrum Fig 2 of NBP2 and NBK2 have 
showed characteristic peaks at 3732.60 cm-1, 3383.80cm-1, 
1647.36cm-1 and 3528.12cm-1, 3385.38cm-1, 1647.36cm-1 
for –OH, -NH, -C=O stretching respectively. Shift of peaks 
in the FT-IR spectrum of these formulations indicates the 
interaction between drug and polymer. 
3.6 In-vitro Dissolution Studies: - 
The release rate profiles were drawn as the percent drug 
released (vs) time. The inclusion complexes of NFV: β-CD 
released upto 93 to 96% & 75 to 96% of drug in 30 minutes 
in distilled water and phosphate buffer respectively. 
Whereas pure drug could release only 12.46% & 34.54% of 
drug in 120 min. in distilled water & phosphate buffer 
respectively. (As shown in Table no.1 & 2). 
 
Fig.2: -FTIR Spectrum of pure drug, polymer & 
various formulations 
 NFV 
                           
  -CD 
 
  NBP2 
 
   NBK2 
 
 NBC2 
 
 
  
Time(min) Pure 
Drug 
NBP1 NBP2 NBK1 NBK2 NBC2 
0 0 0 0 0 0 0 
5 4.8 38.64 42 42.96 40.32 43.44 
10 6.8 56.64 54.96 67.43 58.08 62.39 
15 8.3 71.27 71.52 78.23 74.15 76.31 
20 8.35 91.43 86.15 85.91 88.55 84.13 
30 10.60 96.23 95.51 93.83 96.95 93.59 
45 11.54 96.95 99.59 98.39 98.63 96.23 
60 11.59 105.35 101.03 99.59 101.51 99.35 
90 11.90      
120 12.46      
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Table No.2 -Dissolution Studies of Nelfinavir Complexes  
Time(min) Pure 
Drug 
NBP1 NBP2 NBK1 NBK2 NBC2 
0 0 0 0 0 0 0 
5 10.0 44.64 45.84 49.44 42.96 34.32 
10 12.48 46.15 71.51 63.11 63.11 47.52 
15 14.02 75.83 75.83 78.95 74.87 54.96 
20 20.40 86.39 88.55 88.55 81.83 65.99 
30 21.33 96.23 91.67 93.35 90.95 75.83 
45 32.40 98.87 94.31 101.51 93.35 84.71 
60 34.08 104.63 99.83   90.95 
90 34.08       
120 34.54       
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X-RD of complexes of NFV: β-CD the PM (NBP1) is 
simply the superimposition of each component indicating 
no formation of new structure. Complex prepared by 
coprecipation (NBC1) method showed a diffraction pattern 
quite similar to that of PM, while those obtained from KM 
(NBK1) showed less peaks with low intensity. This 
indicates that the inclusion complex prepared by KM is less 
crystalline than the complex prepared by physical mixture 
& coprecipitation method.When compared with the 
characteristic peak values of pure drug. This shift in the 
values of peaks indicates the interaction between drug & 
polymerThe enhancement in the dissolution rate has been 
found due to the formation of an inclusion complex in the 
solid state and reduction in the crystallanity of the product 
as confirmed by X-RD studies.β-CD can be used to prepare 
NFV inclusion complexes. Solubility of NFV in water & 
phosphate buffer was improved greatly as a result of 
complex formation with β-CD in comparison to pure NFV. 
A marked increase in the dissolution of NFV with β-CD at 
1:2M ratios prepared by kneading and coprecipitation 
method was obtained. NFV-CD complexation results in an 
increase of solubility & dissolution rate for the drug 
suggesting a possible enhancement of its oral 
bioavailability. 
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